Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression

Overview of attention for article published in Cancer Imaging, January 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#2 of 682)
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

So far, Altmetric has seen 60 X posts from 54 X users, with an upper bound of 93,336 followers.

RT @DrMHofman: Saw another patient this week misclassified as progression on DOTATATE PET/CT when the change was likely due to commencement…

RT @DrMHofman: Saw another patient this week misclassified as progression on DOTATATE PET/CT when the change was likely due to commencement…

RT @DrMHofman: Saw another patient this week misclassified as progression on DOTATATE PET/CT when the change was likely due to commencement…

RT @DrMHofman: Saw another patient this week misclassified as progression on DOTATATE PET/CT when the change was likely due to commencement…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 56 additional X posts.